Staphylococcus Aureus Infections
Conditions
Keywords
MSSA, MRSA
Brief summary
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Inpatients (adults and children) at Mayo Clinic, Rochester with sterile source S. aureus cultures (both control and intervention periods) 2. Above, with rapid PBP2a testing (intervention period only).
Exclusion criteria
1. Patients with polymicrobial cultures (i.e., growth of S. aureus plus other organisms in the culture). 2. Patients who have not provided MN authorization to use their medical records for research. 3. Patients who have had the FilmArray Blood culture identification diagnostic test performed on an index S. aureus blood culture. 4. Patients who have had a sterile source S. aureus culture within the prior 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time (hours) to optimal antimicrobial therapy for patients with MSSA and MRSA infections in the pre-intervention and post-intervention periods | within first 7 days of culture result |
Secondary
| Measure | Time frame |
|---|---|
| Time (in hours) to identification of MRSA. | within first 3 days of culture result |
| Vancomycin days of therapy following S. aureus culture result | during the 2 weeks following culture result |
Other
| Measure | Time frame | Description |
|---|---|---|
| Length of hospitalization | from time of culture result to hospital discharge, an expected average duration of 4 weeks | — |
| Total healthcare costs (broken down by bed, laboratory, and pharmacy costs). | from time of culture result to time of hospital discharge, an expected average duration of 4 weeks | participants will be followed for the duration of hospital stay following positive culture result, an expected average of 4 weeks. |
| Proportion of patients with MSSA infection who are switched from an MRSA-active drug to an MSSA-active drug . | within 48 hours of Gram-stain result | — |
| Proportion of patients where the pharmacist contacted the service to modify therapy | wihtin first 7 days after culture result | — |
| Proportion of patients where a electronic (P-care) rule flagged for discordant therapy for the PBP2a result | within first 3 days after culture result | — |
| Duration of bacteremia in patients with MSSA or MRSA bloodstream infections | within first 30 days of culture result | — |
| Time to contact isolation in patients with MRSA infections | within first 7 days of culture result | — |
Countries
United States
Outcome results
None listed